By turning a staple protein in every cell into a drug, the virus that causes the Middle East Respiratory Syndrome or MERS can now stopped, says research.

TOP INSIGHT
The researchers have to find the right way to deliver the engineered protein in the body, before developing it into a medicine.
MERS is similar to SARS, the virus that killed almost 800 people in a 2002 global epidemic.
Like many viruses, MERS works by hijacking the ubiquitin system in human cells composed of hundreds of proteins that rely on ubiquitin to keep the cells alive and well.
Upon infection, viral enzymes alter ubiquitin pathways in a way that allows the virus to evade the immune defence while multiplying and destroying the host tissue as it spreads in the body.
"Viruses have evolved proteins that allow them to hijack host proteins. We can now devise strategies to prevent this from happening," Zhang said.
These synthetic ubiquitin variants act quickly, completely eliminating MERS from cells in a dish within 24 hours.
And they are designed to only target only the virus, hopefully minimising side effects in any future drug.
But before these engineered proteins can be developed into medicine, researchers first must find a way to deliver them into the right part of the body.
"We are also working on an engineered ubiquitin that targets a corn virus responsible for destroying large swathes of corn fields in North America," Zhang said.
Source-IANS
MEDINDIA



Email








